Global Intermediate CDMO Market Research Report 2024

Publication ID:

PB508240596

Publication Date:

August 31, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

The global Intermediate CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Intermediate CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Intermediate CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Intermediate CDMO in Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Intermediate CDMO include Pharmira, AGC Inc, Blue Jet Healthcare, Drug Discovery Alliances, KriSan Biotech, Saurav Chemicals, Olon SpA, AGC Biologics and Fermion, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Intermediate CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intermediate CDMO.
Report Scope
The Intermediate CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Intermediate CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Intermediate CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pharmira
AGC Inc
Blue Jet Healthcare
Drug Discovery Alliances
KriSan Biotech
Saurav Chemicals
Olon SpA
AGC Biologics
Fermion
Pfizer CentreOne
Aspen Holdings
Educell
Hovione
Porton Pharma Solutions
Sinopep
Chongqing Huapont Pharmaceutical
Langhua Pharmaceutical
Segment by Type
Antibiotic Intermediates
Antipyretic and Analgesic Intermediate
Cardiovascular System Drug Intermediates
Anticancer Drug Intermediates
Segment by Application
Pharmaceutical Company
Biotechnology Company
Generic Company
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Intermediate CDMO companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Intermediate CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antibiotic Intermediates
1.2.3 Antipyretic and Analgesic Intermediate
1.2.4 Cardiovascular System Drug Intermediates
1.2.5 Anticancer Drug Intermediates
1.3 Market by Application
1.3.1 Global Intermediate CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Generic Company
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Intermediate CDMO Market Perspective (2019-2030)
2.2 Intermediate CDMO Growth Trends by Region
2.2.1 Global Intermediate CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Intermediate CDMO Historic Market Size by Region (2019-2024)
2.2.3 Intermediate CDMO Forecasted Market Size by Region (2025-2030)
2.3 Intermediate CDMO Market Dynamics
2.3.1 Intermediate CDMO Industry Trends
2.3.2 Intermediate CDMO Market Drivers
2.3.3 Intermediate CDMO Market Challenges
2.3.4 Intermediate CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Intermediate CDMO Players by Revenue
3.1.1 Global Top Intermediate CDMO Players by Revenue (2019-2024)
3.1.2 Global Intermediate CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Intermediate CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Intermediate CDMO Revenue
3.4 Global Intermediate CDMO Market Concentration Ratio
3.4.1 Global Intermediate CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Intermediate CDMO Revenue in 2023
3.5 Intermediate CDMO Key Players Head office and Area Served
3.6 Key Players Intermediate CDMO Product Solution and Service
3.7 Date of Enter into Intermediate CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Intermediate CDMO Breakdown Data by Type
4.1 Global Intermediate CDMO Historic Market Size by Type (2019-2024)
4.2 Global Intermediate CDMO Forecasted Market Size by Type (2025-2030)
5 Intermediate CDMO Breakdown Data by Application
5.1 Global Intermediate CDMO Historic Market Size by Application (2019-2024)
5.2 Global Intermediate CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Intermediate CDMO Market Size (2019-2030)
6.2 North America Intermediate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Intermediate CDMO Market Size by Country (2019-2024)
6.4 North America Intermediate CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Intermediate CDMO Market Size (2019-2030)
7.2 Europe Intermediate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Intermediate CDMO Market Size by Country (2019-2024)
7.4 Europe Intermediate CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Intermediate CDMO Market Size (2019-2030)
8.2 Asia-Pacific Intermediate CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Intermediate CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Intermediate CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Intermediate CDMO Market Size (2019-2030)
9.2 Latin America Intermediate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Intermediate CDMO Market Size by Country (2019-2024)
9.4 Latin America Intermediate CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Intermediate CDMO Market Size (2019-2030)
10.2 Middle East & Africa Intermediate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Intermediate CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Intermediate CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pharmira
11.1.1 Pharmira Company Detail
11.1.2 Pharmira Business Overview
11.1.3 Pharmira Intermediate CDMO Introduction
11.1.4 Pharmira Revenue in Intermediate CDMO Business (2019-2024)
11.1.5 Pharmira Recent Development
11.2 AGC Inc
11.2.1 AGC Inc Company Detail
11.2.2 AGC Inc Business Overview
11.2.3 AGC Inc Intermediate CDMO Introduction
11.2.4 AGC Inc Revenue in Intermediate CDMO Business (2019-2024)
11.2.5 AGC Inc Recent Development
11.3 Blue Jet Healthcare
11.3.1 Blue Jet Healthcare Company Detail
11.3.2 Blue Jet Healthcare Business Overview
11.3.3 Blue Jet Healthcare Intermediate CDMO Introduction
11.3.4 Blue Jet Healthcare Revenue in Intermediate CDMO Business (2019-2024)
11.3.5 Blue Jet Healthcare Recent Development
11.4 Drug Discovery Alliances
11.4.1 Drug Discovery Alliances Company Detail
11.4.2 Drug Discovery Alliances Business Overview
11.4.3 Drug Discovery Alliances Intermediate CDMO Introduction
11.4.4 Drug Discovery Alliances Revenue in Intermediate CDMO Business (2019-2024)
11.4.5 Drug Discovery Alliances Recent Development
11.5 KriSan Biotech
11.5.1 KriSan Biotech Company Detail
11.5.2 KriSan Biotech Business Overview
11.5.3 KriSan Biotech Intermediate CDMO Introduction
11.5.4 KriSan Biotech Revenue in Intermediate CDMO Business (2019-2024)
11.5.5 KriSan Biotech Recent Development
11.6 Saurav Chemicals
11.6.1 Saurav Chemicals Company Detail
11.6.2 Saurav Chemicals Business Overview
11.6.3 Saurav Chemicals Intermediate CDMO Introduction
11.6.4 Saurav Chemicals Revenue in Intermediate CDMO Business (2019-2024)
11.6.5 Saurav Chemicals Recent Development
11.7 Olon SpA
11.7.1 Olon SpA Company Detail
11.7.2 Olon SpA Business Overview
11.7.3 Olon SpA Intermediate CDMO Introduction
11.7.4 Olon SpA Revenue in Intermediate CDMO Business (2019-2024)
11.7.5 Olon SpA Recent Development
11.8 AGC Biologics
11.8.1 AGC Biologics Company Detail
11.8.2 AGC Biologics Business Overview
11.8.3 AGC Biologics Intermediate CDMO Introduction
11.8.4 AGC Biologics Revenue in Intermediate CDMO Business (2019-2024)
11.8.5 AGC Biologics Recent Development
11.9 Fermion
11.9.1 Fermion Company Detail
11.9.2 Fermion Business Overview
11.9.3 Fermion Intermediate CDMO Introduction
11.9.4 Fermion Revenue in Intermediate CDMO Business (2019-2024)
11.9.5 Fermion Recent Development
11.10 Pfizer CentreOne
11.10.1 Pfizer CentreOne Company Detail
11.10.2 Pfizer CentreOne Business Overview
11.10.3 Pfizer CentreOne Intermediate CDMO Introduction
11.10.4 Pfizer CentreOne Revenue in Intermediate CDMO Business (2019-2024)
11.10.5 Pfizer CentreOne Recent Development
11.11 Aspen Holdings
11.11.1 Aspen Holdings Company Detail
11.11.2 Aspen Holdings Business Overview
11.11.3 Aspen Holdings Intermediate CDMO Introduction
11.11.4 Aspen Holdings Revenue in Intermediate CDMO Business (2019-2024)
11.11.5 Aspen Holdings Recent Development
11.12 Educell
11.12.1 Educell Company Detail
11.12.2 Educell Business Overview
11.12.3 Educell Intermediate CDMO Introduction
11.12.4 Educell Revenue in Intermediate CDMO Business (2019-2024)
11.12.5 Educell Recent Development
11.13 Hovione
11.13.1 Hovione Company Detail
11.13.2 Hovione Business Overview
11.13.3 Hovione Intermediate CDMO Introduction
11.13.4 Hovione Revenue in Intermediate CDMO Business (2019-2024)
11.13.5 Hovione Recent Development
11.14 Porton Pharma Solutions
11.14.1 Porton Pharma Solutions Company Detail
11.14.2 Porton Pharma Solutions Business Overview
11.14.3 Porton Pharma Solutions Intermediate CDMO Introduction
11.14.4 Porton Pharma Solutions Revenue in Intermediate CDMO Business (2019-2024)
11.14.5 Porton Pharma Solutions Recent Development
11.15 Sinopep
11.15.1 Sinopep Company Detail
11.15.2 Sinopep Business Overview
11.15.3 Sinopep Intermediate CDMO Introduction
11.15.4 Sinopep Revenue in Intermediate CDMO Business (2019-2024)
11.15.5 Sinopep Recent Development
11.16 Chongqing Huapont Pharmaceutical
11.16.1 Chongqing Huapont Pharmaceutical Company Detail
11.16.2 Chongqing Huapont Pharmaceutical Business Overview
11.16.3 Chongqing Huapont Pharmaceutical Intermediate CDMO Introduction
11.16.4 Chongqing Huapont Pharmaceutical Revenue in Intermediate CDMO Business (2019-2024)
11.16.5 Chongqing Huapont Pharmaceutical Recent Development
11.17 Langhua Pharmaceutical
11.17.1 Langhua Pharmaceutical Company Detail
11.17.2 Langhua Pharmaceutical Business Overview
11.17.3 Langhua Pharmaceutical Intermediate CDMO Introduction
11.17.4 Langhua Pharmaceutical Revenue in Intermediate CDMO Business (2019-2024)
11.17.5 Langhua Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pharmira
AGC Inc
Blue Jet Healthcare
Drug Discovery Alliances
KriSan Biotech
Saurav Chemicals
Olon SpA
AGC Biologics
Fermion
Pfizer CentreOne
Aspen Holdings
Educell
Hovione
Porton Pharma Solutions
Sinopep
Chongqing Huapont Pharmaceutical
Langhua Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂